NO20064130L - Antineoplastiske kombinasjoner av CCI-779 og rituximab - Google Patents

Antineoplastiske kombinasjoner av CCI-779 og rituximab

Info

Publication number
NO20064130L
NO20064130L NO20064130A NO20064130A NO20064130L NO 20064130 L NO20064130 L NO 20064130L NO 20064130 A NO20064130 A NO 20064130A NO 20064130 A NO20064130 A NO 20064130A NO 20064130 L NO20064130 L NO 20064130L
Authority
NO
Norway
Prior art keywords
cci
rituximab
antineoplastic combinations
antineoplastic
combinations
Prior art date
Application number
NO20064130A
Other languages
English (en)
Norwegian (no)
Inventor
Eliel Bayever
Laurence Moore
Lee F Allen
Lewis C Strauss
Mattew L Sherman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064130(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20064130L publication Critical patent/NO20064130L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20064130A 2004-03-11 2006-09-13 Antineoplastiske kombinasjoner av CCI-779 og rituximab NO20064130L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55212204P 2004-03-11 2004-03-11
PCT/US2005/007724 WO2005087265A1 (en) 2004-03-11 2005-03-09 Antineoplastic combinations of cci-779 and rituximab

Publications (1)

Publication Number Publication Date
NO20064130L true NO20064130L (no) 2006-10-10

Family

ID=34964832

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064130A NO20064130L (no) 2004-03-11 2006-09-13 Antineoplastiske kombinasjoner av CCI-779 og rituximab

Country Status (21)

Country Link
US (1) US20050272758A1 (pt)
EP (1) EP1722817A1 (pt)
JP (1) JP2007528399A (pt)
KR (1) KR20070027510A (pt)
CN (1) CN1929863A (pt)
AR (1) AR047988A1 (pt)
AU (1) AU2005221675A1 (pt)
BR (1) BRPI0508451A (pt)
CA (1) CA2557005A1 (pt)
CR (1) CR8571A (pt)
EC (1) ECSP066835A (pt)
GT (1) GT200500040A (pt)
IL (1) IL177565A0 (pt)
NO (1) NO20064130L (pt)
PA (1) PA8625801A1 (pt)
PE (1) PE20060002A1 (pt)
RU (1) RU2389508C2 (pt)
SG (1) SG150559A1 (pt)
SV (1) SV2005002048A (pt)
TW (1) TW200539869A (pt)
WO (1) WO2005087265A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
JP2006306743A (ja) * 2005-04-26 2006-11-09 Hamamatsu Photonics Kk 体液処理方法
RU2423381C2 (ru) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
EP1942937A1 (en) * 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
WO2008116163A1 (en) * 2007-03-22 2008-09-25 Oregon Health & Science University Therapeutic drug combinations for treatment of b-cell malignancies
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
RU2531754C2 (ru) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
WO2010057047A1 (en) * 2008-11-13 2010-05-20 Trubion Pharmaceutics, Inc. Cd37 immunotherapeutic combination therapies and uses thereof
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
US20130028895A1 (en) * 2011-07-27 2013-01-31 Gerald Wulf Exosome inhibiting agents and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
RU2218179C2 (ru) * 1996-06-17 2003-12-10 Гилфорд Фармасьютикалз Инк. СПОСОБЫ ЛЕЧЕНИЯ РАКА С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ NAALADазы
US6875451B2 (en) * 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
ATE411321T1 (de) * 2000-09-19 2008-10-15 Wyeth Corp Wasserlösliche rapamycin-ester
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
RU2306952C2 (ru) * 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
UA78706C2 (en) * 2001-06-01 2007-04-25 Wyeth Corp Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
BR0306858A (pt) * 2002-01-10 2004-11-03 Novartis Ag Sistemas de liberação de drogas para a prevenção e tratamento de doenças vasculares compreendendo rapamicina e derivados da mesma
DE10306724A1 (de) * 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
DE602004004520T2 (de) * 2003-04-22 2007-11-08 Wyeth Antineoplastische zusammensetzungen
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto

Also Published As

Publication number Publication date
JP2007528399A (ja) 2007-10-11
PE20060002A1 (es) 2006-02-14
GT200500040A (es) 2005-10-24
US20050272758A1 (en) 2005-12-08
SG150559A1 (en) 2009-03-30
CN1929863A (zh) 2007-03-14
ECSP066835A (es) 2006-11-24
AU2005221675A1 (en) 2005-09-22
WO2005087265A8 (en) 2006-10-05
KR20070027510A (ko) 2007-03-09
AR047988A1 (es) 2006-03-15
CR8571A (es) 2007-02-05
SV2005002048A (es) 2005-11-04
RU2389508C2 (ru) 2010-05-20
WO2005087265A1 (en) 2005-09-22
IL177565A0 (en) 2006-12-10
EP1722817A1 (en) 2006-11-22
RU2006130623A (ru) 2008-04-20
PA8625801A1 (es) 2006-06-02
TW200539869A (en) 2005-12-16
CA2557005A1 (en) 2005-09-22
BRPI0508451A (pt) 2007-07-24

Similar Documents

Publication Publication Date Title
NO20064130L (no) Antineoplastiske kombinasjoner av CCI-779 og rituximab
BR0211769A (pt) Combinações antineoplásicas
AU2003237367A1 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
ATE414514T1 (de) Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
DE602004023503D1 (de) Medizinisches behandlungswerkzeug und dieses entha
DE60317873D1 (de) Dünne und trockene Windel
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
EP1721526A4 (en) BREAD ENHANCER AND THIS BREAD CONTAINING
NO20054133L (no) Antineoplastiske kombinasjoner omfattende at rapamycin derivat og en aromatase inhibitor
BRPI0409632A (pt) combinações antineoplásticas
IL174864A0 (en) A therapeutic combination of vx-497 and ribavirin and kits containing the same
FR2834459B1 (fr) Agent microbicide et composition de traitement cosmetique le contenant
IL163900A (en) Antibody which binds to tpte for use in diagnosing, monitoring, preventing or treating cancer disease and pharmaceutical compositions comprising said antibody
IS6967A (is) Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
AU2003274963A1 (en) Mda-7 and free radicals in the treatment of cancer
FR2831430B1 (fr) Composition cosmetique et/ou de soin contenant un polyester-siloxane filmogene, non reticule
EP1613585A4 (en) COMPOUNDS AND METHOD FOR USE IN THE TREATMENT OF NEOPLASMS AND CANCER BASED ON INHIBITORS OF ISOPRENYLCYSTEIN METHYLTRANSFERASE
SG110107A1 (en) Compound and use in treatment
SG112006A1 (en) Radioactive arsenic-containing compounds and their uses in the treatment of tumors
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003270350A1 (en) Isoxazoles and their use in the treatment of ischemic diseases
AU2004281077A1 (en) Methods and agents for the treatment of cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application